Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $0.62 in the prior trading day, Mersana Therapeutics Inc (NASDAQ: MRSN) closed at $0.63, up 2.01%. In other words, the price has increased by $2.01 from its previous closing price. On the day, 9.65 million shares were traded. MRSN stock price reached its highest trading level at $0.715 during the session, while it also had its lowest trading level at $0.6144.
Ratios:
Our goal is to gain a better understanding of MRSN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.35 and its Current Ratio is at 2.35. In the meantime, Its Debt-to-Equity ratio is 30.00 whereas as Long-Term Debt/Eq ratio is at 15.51.
On March 19, 2024, JP Morgan Upgraded its rating to Neutral which previously was Underweight but kept the price unchanged to $5.
Wedbush Upgraded its Neutral to Outperform on February 29, 2024, whereas the target price for the stock was revised from $2 to $7.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 28 ’24 when Bala Mohan sold 1,884 shares for $1.90 per share. The transaction valued at 3,580 led to the insider holds 54,731 shares of the business.
Bala, Mohan bought 1,884 shares of MRSN for $3,843 on Oct 28 ’24. On Oct 02 ’24, another insider, DeSchuytner Brian, who serves as the SVP, COO & CFO of the company, sold 8,089 shares for $2.00 each. As a result, the insider received 16,178 and left with 100,422 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRSN now has a Market Capitalization of 78319920. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.25 while its Price-to-Book (P/B) ratio in mrq is 74.24.
Stock Price History:
The Beta on a monthly basis for MRSN is 1.50, which has changed by -0.7847751 over the last 52 weeks, in comparison to a change of 0.23147523 over the same period for the S&P500. Over the past 52 weeks, MRSN has reached a high of $6.28, while it has fallen to a 52-week low of $0.60. The 50-Day Moving Average of the stock is -67.33%, while the 200-Day Moving Average is calculated to be -71.23%.
Shares Statistics:
The stock has traded on average 2.50M shares per day over the past 3-months and 9505260 shares per day over the last 10 days, according to various share statistics. A total of 122.87M shares are outstanding, with a floating share count of 86.56M. Insiders hold about 29.93% of the company’s shares, while institutions hold 59.60% stake in the company. Shares short for MRSN as of 1735603200 were 8849970 with a Short Ratio of 3.54, compared to 1732838400 on 8752309. Therefore, it implies a Short% of Shares Outstanding of 8849970 and a Short% of Float of 9.4.
Earnings Estimates
The current assessment of Mersana Therapeutics Inc (MRSN) involves the perspectives of 5.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.17, with high estimates of -$0.14 and low estimates of -$0.2.
Analysts are recommending an EPS of between -$0.55 and -$0.65 for the fiscal current year, implying an average EPS of -$0.59. EPS for the following year is -$0.7, with 5.0 analysts recommending between -$0.5 and -$0.86.
Revenue Estimates
10 analysts predict $7.64M in revenue for the current quarter. It ranges from a high estimate of $12.6M to a low estimate of $1M. As of the current estimate, Mersana Therapeutics Inc’s year-ago sales were $10.7M
A total of 10 analysts have provided revenue estimates for MRSN’s current fiscal year. The highest revenue estimate was $36.73M, while the lowest revenue estimate was $25.14M, resulting in an average revenue estimate of $31.75M. In the same quarter a year ago, actual revenue was $36.85M
